- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03896932
Minipooled-IVIG in Primary Immunodeficiency Disease
Study of Safety and Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Primary Immunodeficiency Patients
- study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG)
Study the safety and efficacy of a newly developed preparation of MP-IVIG in children with primary immunodeficiency (PID) :
- Adverse reaction of MP-IVIG(anaphylaxis and haemolysis)( no or mild or moderate)
- Prevention of severe bacterial infection
- Improvement of general health(weight gain and mentality)
- Integration in to social live
- Compare the efficacy of MP-IVIG to standard IVIG in children with primary immunodeficiency (PID).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders of the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity, and malignancies. Clinical descriptions have already been made for more than 200 PIDs, for which over 150 forms of PID have been molecularly characterized .
A population prevalence of diagnosed PID in the United States at approximately 1 in 1,200 persons.
A part from local registration in some centres there is no national registry of PID in Egypt, and hence, the prevalence of these disorders in the investigator's population is still unknown .
An increasing number of PID are recognized, and effective treatments are possible. Early use of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ damage and improve long quality of life in these patients .
Immunoglobulin G (IgG) is an essential plasma derived medicine that is lacking in developing countries .IgG shortages leave immune deficient patients without treatment, exposing them to devastating recurrent infections from local pathogens. A simple and practical method for producing IgG from normal plasma collected in developing countries is needed to provide better, faster access to IgG for patients .
Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion as well as minipool S/D-F cryoprecipitate to treat bleeding disorders.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Assiut, Ägypten
- Faculty of medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age group: children patients under 18 years.
- The study will include patient diagnosed as primary immunodeficiency disease (PID) in Assiut university hospital on standard IVIG therapy.
Exclusion Criteria:
- Patient has SCID.
- Patient with history of severe IVIG side effect.
- Patient with severe immunodeficiency and has severe disseminated infection.
- Patient with renal impairment
- Patient with hepatic cell failure
- Patient with endocrinal abnormalities
- patient with secondary immunodeficiency diseases
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: minipooled- Intravenous immunoglobulin(MP-IVIG)
• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.
|
The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH.
The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Efficacy of MP-IVIG assessed by the incidence of acute Serious Bacterial infections(SBIs)
Zeitfenster: 1 year
|
The rate of Acute SBIs for each participant per 1 year will be assessed by questionnaire (Serious Bacterial Infections) include sign and symptoms of acute serious bacterial infections, i.e. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, osteomyelitis/ septic arthritis, visceral abscess.
|
1 year
|
Safty of MP-IVIG assessed by percentage of adverse Events
Zeitfenster: 72 hour after adminstration of MP-IVIG and betwen infusions period
|
Overall percentage of adverse events as hemolysis and anaphylaxis headache and other complains that occur during 72 hours of following an infusion of MP-IVIG will be assessed by1) vital sign(pulse,blood pressure,Respiratory rate and temprature 2)Hemolysis by hemoglobin level,LDH,billirubin level.2)lbetwen
infusions by home diaries.
|
72 hour after adminstration of MP-IVIG and betwen infusions period
|
Study the pharmacokinetics- MP-IVIG trough levels
Zeitfenster: predose sample
|
MP-IVIG trough level concentration values of serum total IgG pre the MP-IVIG infusion (if applicable). |
predose sample
|
Study the pharmacokinetics MP-IVIG plasma concentration -time curve
Zeitfenster: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Blood samples for analysis of pharmacokinetics MP-IVIG plasma concentration -time curve were obtained and analysed
|
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Study the pharmacokinetics MP-IVIG half-life
Zeitfenster: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed
|
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Study the pharmacokinetics MP-IVIG area under the curve
Zeitfenster: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Blood samples for analysis of pharmacokinetics MP-IVIG haf-life were obtained and analysed
|
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Study the pharmacokinetics MP-IVIG Cmax
Zeitfenster: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Blood samples for analysis of pharmacokinetics MP-IVIG Cmax were obtained and analysed
|
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Study the pharmacokinetics of MP-IVIG-Tmax.
Zeitfenster: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Blood samples for analysis of pharmacokinetics MP-IVIG Tmax were obtained and analysed
|
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Study the pharmacokinetics of MP-IVIG elimination rate constant(s).
Zeitfenster: (1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Blood samples for analysis of pharmacokinetics MP-IVIG elimination rate constant(s) were obtained and analysed
|
(1 hour, 2 hours and 1, 2, 3, 7, 14 and 21 days) post-dose
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Compare efficacy of MP-IVIG vs standard IVIG by compare incidence of SBIs of both
Zeitfenster: 1 year
|
• Compare the efficacy of MP-IVIG to standard IVIG in children with Primary immunodeficiency disease (PID).
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Maha A Mohammed, professor, Assiut University
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, de Melo L, Soulie V, Adam J, Burnouf T. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2010 Feb;20(1):48-61. doi: 10.1111/j.1365-3148.2009.00963.x. Epub 2009 Sep 23.
- Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol. 2007 Sep;27(5):497-502. doi: 10.1007/s10875-007-9103-1. Epub 2007 Jun 19.
- Reda SM, Afifi HM, Amine MM. Primary immunodeficiency diseases in Egyptian children: a single-center study. J Clin Immunol. 2009 May;29(3):343-51. doi: 10.1007/s10875-008-9260-x. Epub 2008 Nov 11.
- Piguet D, Tosi C, Luthi JM, Andresen I, Juge O; Study investigators. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions. Clin Exp Immunol. 2008 Apr;152(1):45-9. doi: 10.1111/j.1365-2249.2008.03597.x. Epub 2008 Jan 28.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- IVIG in PID
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Primäre Immunschwäche
-
Oslo University HospitalAbgeschlossen
-
IMMUNOe Research CentersAbgeschlossenCVI – Common Variable ImmunodeficiencyVereinigte Staaten
-
Janssen-Cilag International NVAbgeschlossenInfektionen mit dem Human Immunodeficiency Virus (HIV). | Erworbenes Immunschwächesyndrom (AIDS)-VirusFrankreich, Vereinigtes Königreich, Belgien, Deutschland, Spanien, Schweiz, Dänemark, Israel, Österreich, Polen, Ungarn, Schweden, Irland
-
Merck Sharp & Dohme LLCZurückgezogenInfektionen mit dem Human Immunodeficiency Virus (HIV).
-
Johns Hopkins UniversityNational Institutes of Health (NIH)AbgeschlossenHuman Immunodeficiency Virus Positiv oder NegativVereinigte Staaten
-
Novartis PharmaceuticalsAbgeschlossenCommon Variable Immunodeficiency (CVID), APDS / PASLIDeutschland, Russische Föderation, Irland, Italien, Vereinigtes Königreich, Weißrussland, Niederlande, Tschechien, Vereinigte Staaten
-
University of California, Los AngelesJeffrey Modell FoundationUnbekanntCVI – Common Variable ImmunodeficiencyVereinigte Staaten
-
Merck Sharp & Dohme LLCAbgeschlossenInfektion mit dem Human Immunodeficiency Virus (HIV).Vereinigte Staaten, Deutschland
-
ViiV HealthcareGlaxoSmithKlineBeendetInfektion, Human Immunodeficiency Virus IVereinigte Staaten, Kanada, Puerto Rico
-
ViiV HealthcareGlaxoSmithKlineAbgeschlossen
Klinische Studien zur minipooled- Intravenous immunoglobulin(MP-IVIG)
-
Brigham and Women's HospitalAlexion PharmaceuticalsBeendetAntikörper-vermittelte Abstoßung | Humorale AblehnungVereinigte Staaten
-
Assiut UniversityUnbekanntGuillain Barre-Syndrom
-
North American Consortium for HistiocytosisHistiocyte SocietyRekrutierungLangerhans-Zell-HistiozytoseVereinigte Staaten